Wednesday Morning Session: Energy, Petroleum, and Biofuels: Advances in Sample Preparation and MS Interface Design
This Wednesday morning session (WOA) will take place in Exhibit Hall AB from 8:30–10:30 a.m. Mark Lowenthall of the National Institute of Standards and Technology (NIST) will preside.
This Wednesday morning session (WOA) will take place in Exhibit Hall AB from 8:30–10:30 a.m. Mark Lowenthall of the National Institute of Standards and Technology (NIST) will preside.
The first talk in this session is titled “Combining Metal Ion Complexation and Ultrahigh Resolution Mass Spectrometry for the Selective Analysis of Nitrogen Compounds in Asphaltenes.” Wolfgang Schrader of the Max-Planck Inst. für Kohlenforschun in Mülheim / Ruhr, Germany will present.
Next, Mckay Easton of Purdue University in West Lafayette, Indiana will present. Easton’s talk is titled “A Combined Experimental and Computational Study on the Reaction Pathways of Fast Pyrolysis of Cellobiose.”
Michael T. Cheng of Chevron Research in Richmond, California will talk next. Cheng’s presentation is titled “Detailed Characterization of Crude Oil and Its Fractions, Is Mass Spectrometry Sufficient?”
After Cheng, Steven M. Rowland of Florida State University in Tallahassee, Florida will present. Rowland’s talk is titled “Separation-Enhanced Characterization of Oxygenated Petroleum Compounds by Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FT-ICR MS).”
Arne Ulbrich of the University of Wisconsin in Madison, Wisconsin is next with a talk titled “Characterization and Quantification of Fermentation Inhibitors in Biomass Hydrolysates for Biofuel Production.”
Aviv Amirav of Tel-Aviv University in Tel-Aviv, Israel and Aviv Analytical Ltd. will present the last talk in this session. Amirav’s talk is titled “Isomer Distribution Analysis for Improved Hydrocarbon Mixtures Characterization.”
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
